Alterations in regional brain metabolism in genetic and pharmacological models of reduced NMDA receptor function

Brain Research

Volumn 951, Issue 2, 2002, Pages 166-176

  Duncan, Gary E ^a   Miyamoto, Seiya ^a   Gu, Hongbin ^a   Lieberman, Jeffrey A ^a   Koller, Beverly H ^a   Snouwaert, John N ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

NMDA receptor; NR1 hypomorphic mouse

Indexed keywords

AMPA RECEPTOR; DEOXYGLUCOSE; DIZOCILPINE; KAINIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL BEHAVIOR; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN METABOLISM; BRAIN REGION; CAUDATE NUCLEUS; CINGULATE GYRUS; CONTROLLED STUDY; FEMALE; HIPPOCAMPUS; LIGAND BINDING; LOCOMOTION; MALE; MOTOR CORTEX; MOUSE; NEOCORTEX; NONHUMAN; NUCLEUS ACCUMBENS; PHENOTYPE; PREFRONTAL CORTEX; PRIORITY JOURNAL; RECEPTOR BINDING; SOMATOSENSORY CORTEX; THALAMUS;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANIMALS; AUTORADIOGRAPHY; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; DEOXYGLUCOSE; DIZOCILPINE MALEATE; DNA; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; KAINIC ACID; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; PHENOTYPE; RECEPTORS, AMPA; RECEPTORS, KAINIC ACID; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0037019884     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)03156-6     Document Type: Article

References (52)

1. Adler C.M., Goldberg T.E., Malhotra A.K., Pickar D., Breier A. Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biol. Psychiatry. 43:1998;811-816.
2. Adler C.M., Malhotra A.K., Elman I., Goldberg T., Egan M., Pickar D., Breier A. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am. J. Psych. 156:1999;1646-1649.
3. Andreasen N.C., O'Leary D.S., Flaum M., Nopoulos P., Watkins G.L., Boles P.L., Hichwa R.D. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patients. Lancet. 349:1997;1730-1734.
4. Andreasen N.C., Rezai K., Alliger R. Hypofrontality in neuroleptic-naιve patients and in patients with chronic schizophrenia. Arch. Gen. Psychiatry. 49:1992;943-958.
5. Arvanov V.L., Liang X., Schwartz J., Grossman S., Wang R.Y. Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J. Pharmacol. Exp. Ther. 283:1997;226-234.
6. Arvanov V.L., Wang R.Y. Clozapine, but not haloperidol, prevents the functional hyperactivity of N-methyl-D-aspartate receptors in rat cortical neurons induced by subchronic administration of phencyclidine. J. Pharmacol. Exp. Ther. 289:1999;1000-1006.
7. Bakshi V.P., Swerdlow N.R., Geyer M.A. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J. Pharmacol. Exp. Ther. 271:1994;787-794.
8. Bell D. Comparison of amphetamine psychosis and schizophrenia. Am. J. Psych. 111:1965;701-707.
9. Breier A., Malhotra A.K., Pinals D.A., Weisenfeld N.I., Pickar D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am. J. Psych. 154:1997;805-811.
10. Buchsbaum M.S., Hazlett E.A. Positron emission tomography studies of abnormal glucose metabolism in schizophrenia. Schizophr. Bull. 24:1998;343-364.
11. Clark C., Kopala L., Li D.K., Hurwitz T. Regional cerebral glucose metabolism in never-medicated patients with schizophrenia. Can. J. Psychiatry - Revue Canadienne de Psychiatrie. 46:2001;340-345.
12. Corbett R., Camacho F., Woods A.T., Kerman L.L., Fishkin R.J., Brooks K., Dunn R.W. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology. 120:1995;67-74.
13. Coyle J.T. The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Rev. Psychiatry. 3:1996;241-253.
14. Deutsch S.I., Mastropaolo J., Schwartx B.L., Rosse R., Morihisa J.M. A 'glutamatergic hypothesis' of schizophrenia. Clin. Neuropharmacol. 12:1989;1-13.
15. Duncan G.E., Johnson K.B., Breese G.R.T. Topographic patterns of brain activity in response to swim stress: assessment by 2-deoxyglucose uptake and expression of Fos-like immunoreactivity. J. Neurosci. 13:1993;3932-3943.
16. Duncan G.E., Leipzig J.N., Mailman R.B., Lieberman J.A. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res. 812:1998;65-75.
17. Duncan G.E., Miyamoto S., Leipzig J.N., Lieberman J.A. Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. Brain Res. 843:1999;171-183.
18. Duncan G.E., Miyamoto S., Leipzig J.N., Lieberman J.A. Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism. J. Pharmacol. Exp. Ther. 293:2000;8-14.
19. Duncan G.E., Moy S.S., Knapp D.J., Mueller R.A., Breese G.R. Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia. Brain Res. 787:1998;181-190.
20. Forrest D., Yuzaki M., Soares H.D., Ng L., Luk D.C., Sheng M., Stewart C.L., Morgan J.I., Connor J.A., Curran T. Targeted disruption of NMDA receptor 1 gene abolishes NMDA response and results in neonatal death. Neuron. 13:1994;325-338.
21. French E.D., Mura A., Wang T. MK-801, phencyclidine (PCP), and PCP-like drugs increase burst firing in rat A10 dopamine neurons: comparison to competitive NMDA antagonists. Synapse. 13:1993;108-116.
22. Hazlett E.A., Buchsbaum M.S., Jeu L.A., Nenadic I., Fleischman M.B., Shihabuddin L., Haznedar M.M., Harvey P.D. Hypofrontality in unmedicated schizophrenia patients studied with PET during performance of a serial verbal learning task. Schizophr. Res. 43:2000;33-46.
23. Haznedar M.M., Buchsbaum M.S., Luu C., Hazlett E.A., Siegel B.V.J., Lohr J., Wu J., Haier R.J., Bunney W.E. Jr. Decreased anterior cingulate gyrus metabolic rate in schizophrenia. Am. J. Psych. 154:1997;682-684.
24. Holcomb H.H., Lahti A.C., Medoff D.R., Weiler M., Tamminga C.A. Sequential regional cerebral blood flow brain scans using PET with H2(15)O demonstrate ketamine actions in CNS dynamically. Neuropsychopharmacology. 25:2001;165-172.
25. Javitt D.C., Sershen H., Hashim A., Lajtha A. Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide. Neuropsychopharmacology. 17:1997;202-204.
26. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psych. 148:1991;1301-1308.
27. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 20:1999;201-225.
28. Jentsch J.D., Taylor J.R., Elsworth J.D., Redmond D.E.J., Roth R.H. Altered frontal cortical dopaminergic transmission in monkeys after subchronic phencyclidine exposure: involvement in frontostriatal cognitive deficits. Neuroscience. 90:1999;823-832.
29. Kim J.J., Mohamed S., Andreasen N.C., O'Leary D.S., Watkins L., Ponto L.L.B., Hichwa R.D. Regional neural dysfunctions in chronic schizophrenia studied with positron emission tomography. Am. J. Psych. 157:2000;542-548.
30. Kotrla K.J., Weinberger D.R. Brain imaging in schizophrenia. Annu. Rev. Med. 46:1995;113-122.
31. Kramer J.C., Gischman V., Littlefield D. Amphetamine abuse - pattern and effects of high doses taken intravenously. J. Am. Med. Assoc. 201:1967;89-93.
32. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B.J., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry. 51:1994;199-214.
33. Lahti A.C., Holcomb H.H., Medoff D.R., Tamminga C.A. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport. 6:1995;869-872.
34. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 13:1995;9-19.
35. Lahti A.C., Weiler M.A., Tamara M.B., Parwani A., Tamminga C.A. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology. 25:2001;455-467.
36. Lieberman J.A., Kane J.M., Alvir J.A.J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology. 91:1987;415-433.
37. Malhotra A.K., Adler C.M., Kennison S.D., Elman I., Pickar D., Breier A. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol. Psychiatry. 42:1997;664-668.
38. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology. 17:1997;141-150.
39. Miyamoto S., Leipzig J.N., Lieberman J.A., Duncan G.E. Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice. Neuropsychopharmacology. 22:2000;400-412.
40. Miyamoto S., Leipzig J.N., Lieberman J.A., Duncan G.E. Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice. Neuropsychopharmacology. 22:2000;400-412.
41. Miyamoto S., Mailman R.B., Lieberman J.A., Duncan G.E. Blunted brain metabolic response to ketamine in mice lacking D(1A) dopamine receptors. Brain Res. 894:2001;167-180.
42. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotrophic glutamate receptor agonist in rats. Science. 281:1998;1349-1352.
43. Mohn A.R., Gainetdinov R.R., Caron M.G., Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell. 98:1999;427-436.
44. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 52:1995;998-1007.
45. Schmidt C.J., Fadayel G.M. Regional effects of MK-801 on dopamine release effects of competitive NMDA or 5-HT2A receptor blockade. J. Pharmacol. Exp. Ther. 277:1996;1541-1549.
46. Sharp F.R., Tomitaka M., Bernaudin M., Tomitaka S. Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia? Trends Neurosci. 24:2001;330-334.
47. Shihabuddin L., Buchsbaum M.S., Hazlett E.A., Haznedar M.M., Harvey P.D., Newman A., Schnur D.B., Spiegel-Cohen J., Wei T., Machac J., Knesaurek K., Vallabhajosula S., Biren M.A., Ciaravolo T.M., Luu-Hsia C. Dorsal striatal size, shape, and metabolic rate in never-medicated and previously medicated schizophrenics performing a verbal learning task. Arch. Gen. Psychiatry. 55:1998;235-243.
48. Shihabuddin L., Buchsbaum M.S., Hazlett E.A., Silverman J., New A., Brickman A.M., Mitropoulou V., Nunn M., Fleischman M.B., Tang C., Siever L.J. Striatal size and relative glucose metabolic rate in schizotypal personality disorder and schizophrenia. Arch. Gen. Psychiatry. 58:2001;877-884.
49. Swerdlow N.R., Bakshi V.P., Geyer M.A. Seroquel restores sensorimotor gating in phencyclidine-treated rats. J. Pharmacol. Exp. Ther. 279:1996;1290-1299.
50. Tarazi F.I., Florijn W.J., Creese I. Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology. 128:1996;371-379.
51. Verma A., Moghaddam B. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats modulation by dopamine. J. Neurosci. 16:1996;373-379.
52. Weinberger D.R., Berman K.F. Speculation on the meaning of cerebral metabolic hypofrontality in schizophrenia. Schizophr. Bull. 14:1988;157-168.